Drug Profile
CoRectoGen gene therapy - Oxford BioMedica
Latest Information Update: 13 Aug 2003
Price :
$50
*
At a glance
- Originator Oxford BioMedica
- Class Antineoplastics; Gene therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer metastases; Colorectal cancer
Most Recent Events
- 13 Aug 2003 Discontinued - Preclinical for Cancer metastases in United Kingdom (Injection)
- 13 Aug 2003 Discontinued - Preclinical for Colorectal cancer in United Kingdom (Injection)
- 07 Jan 2002 No-Development-Reported for Cancer metastases in United Kingdom (Injection)